Clear Creek Bio is a start up pharmaceutical company developing novel therapeutics for the treatment of cancer.

Work with academic groups in the Pennsylvania and Delaware to translate and develop research strategies for drug and diagnostic products.

I provide research planning and CMC drug development advise to early stage and start-up biotech and pharmaceutical companies.

Working in the laboratory of Dr. Mark Greene to develop strategies of translation of current research programs into development.

LytPhage is a start up biotech company developing novel bacterial virus, bacteriophage, technology to treat life threatening antibiotic resistant infections.

I provided chemistry development support.

Promedior is a start up (March 2006) therapeutic biotech company developing drugs for the treatment of fibrotic diseases. I was responsible for planning, building, and managing the pharmaceutical development portion of Promedior. I also managed the IP portfolio.• Hired a 10 person development team including safety/toxicology and biopharmaceutical manufacturing in 9 months.• Developed from DNA via CMO’s the cloning, expression and cGMP manufacture of 125 kDa protein in 15 months.• Developed preclinical pharmacology programs with 8 leading academic fibrosis research groups.• Completed the execution in 2 years of a preclinical pharmacology, toxicology and CMC data necessary to file the IND submission of PRM-151 a recombinant human protein.

I planned and coordinated all parts of development-phase projects from preclinical to commercial launch. I helped business development evaluate and rank potential in-licensing candidates. I was a member of the due diligence team providing background for prospective partners. • Planned and executed the satraplatin worldwide Phase III satraplatin pivotal trial and US & EU regulator filings.• Organized satraplatin rolling NDA submission and European EMEA filings.• Planned two small molecule CDK antagonists and one in-licensed pre-clinical to Phase I US projects.• Planned and executed the antibody 1D09C3 preclinical to Phase I European project.• Supported partnering negotiations with Pharmion 2005 and other ongoing partnership opportunities.

Lead a research team of 36 persons.